Amedeo Smart

Free Medical Literature Service


 

Amedeo

Peptic Ulcer

  Free Subscription

Articles published in
Aliment Pharmacol Ther
    August 2022
  1. RAYMENANTS K, Tack J
    Editorial: refractory reflux sensitivity-A place for baclofen? Authors' reply.
    Aliment Pharmacol Ther. 2022;56:725-726.
    >> Share

  2. KATZ PO
    Editorial: refractory reflux sensitivity - a place for baclofen?
    Aliment Pharmacol Ther. 2022;56:723-724.
    >> Share

  3. ANG D
    Letter: a promising Helicobacter pylori regimen-vonoprazan-based therapy. Author's reply.
    Aliment Pharmacol Ther. 2022;56:754-755.
    >> Share

  4. HU Y, Lu NH
    Letter: a promising Helicobacter pylori regimen - vonoprazan-based therapy.
    Aliment Pharmacol Ther. 2022;56:752-753.
    >> Share

    July 2022
  5. YEOMANS ND
    Editorial: risk of gastric and duodenal ulcers among new users of low-dose aspirin.
    Aliment Pharmacol Ther. 2022;56:334-335.
    >> Share

  6. RADADIYA D, Devani K, Rockey DC
    Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding-authors' reply.
    Aliment Pharmacol Ther. 2022;56:338-339.
    >> Share

  7. ORPEN-PALMER J, Stanley AJ
    Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2022;56:336-337.
    >> Share

    June 2022
  8. ANG D, Koo SH, Chan YH, Tan TY, et al
    Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2022 Jun 3. doi: 10.1111/apt.17070.
    >> Share

  9. PAUWELS A, Raymenants K, Geeraerts A, Boecxstaens V, et al
    Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2022 Jun 3. doi: 10.1111/apt.17068.
    >> Share

  10. SONNENBERG A
    Letter: birth cohort pattern of Helicobacter pylori infection rates.
    Aliment Pharmacol Ther. 2022;55:1461.
    >> Share

  11. CHEN S, Liu D, Chen H, Liao A, et al
    The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
    Aliment Pharmacol Ther. 2022;55:1524-1533.
    >> Share

    May 2022
  12. NGUYEN TNM, Sha S, Chen LJ, Holleczek B, et al
    Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: Results from two large cohorts with new-user design.
    Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17050.
    >> Share

    February 2022
  13. JIANG F, Guo CG, Leung WK
    Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication-authors' reply.
    Aliment Pharmacol Ther. 2022;55:374-375.
    >> Share

  14. YANG H, Hu B
    Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2022;55:372-373.
    >> Share

    January 2022
  15. ZHENG X, Li N, Zhao J
    Letter: proton pump inhibitors and risk of myocardial infarction.
    Aliment Pharmacol Ther. 2022;55:139-140.
    >> Share

  16. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    Letter: proton pump inhibitors and risk of myocardial infarction-authors' reply.
    Aliment Pharmacol Ther. 2022;55:141-142.
    >> Share

  17. YANG JC, Kao JY
    Treatment considerations in Helicobacter pylori management.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S22-S28.
    >> Share

  18. DORE MP, Graham DY
    Modern approach to the diagnosis of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S14-S21.
    >> Share

  19. SONNENBERG A
    Epidemiology of Helicobacter pylori.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S1-S13.
    >> Share

    November 2021
  20. SUGANO K, Howden CW
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease.
    Aliment Pharmacol Ther. 2021;54:1350-1351.
    >> Share

  21. JIANG F, Guo CG, Leung WK
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:1352-1353.
    >> Share

    October 2021
  22. SCHUITENMAKER JM, Oude Nijhuis RAB, Bredenoord AJ
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:976.
    >> Share

  23. RIBOLSI M, Savarino E
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?
    Aliment Pharmacol Ther. 2021;54:974-975.
    >> Share

    September 2021
  24. JIANG F, Guo CG, Cheung KS, Leung WK, et al
    Long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population-based cohort study.
    Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16604.
    >> Share

  25. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018).
    Aliment Pharmacol Ther. 2021 Sep 3. doi: 10.1111/apt.16565.
    >> Share

  26. BASNAYAKE C, Geeraerts A, Pauwels A, Koek G, et al
    Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment.
    Aliment Pharmacol Ther. 2021;54:755-778.
    >> Share

    August 2021
  27. ZAMANI M, Alizadeh-Tabari S, Hasanpour AH, Eusebi LH, et al
    Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications.
    Aliment Pharmacol Ther. 2021 Aug 26. doi: 10.1111/apt.16585.
    >> Share

  28. ARAI J, Aoki T, Hayakawa Y, Niikura R, et al
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm.
    Aliment Pharmacol Ther. 2021;54:528-529.
    >> Share

  29. LIU Y, Chen M
    Letter: association between the risk of microscopic colitis and use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;54:526-527.
    >> Share

  30. CHEN L, Glance S, Garg M
    Letter: response of eosinophilic oesophagitis to proton pump inhibitor therapy-the importance of biopsies at index endoscopy.
    Aliment Pharmacol Ther. 2021;54:521-522.
    >> Share

  31. LUI TKL, Leung WK
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:530-531.
    >> Share

  32. KATZ P
    Editorial: non-erosive reflux disease is often not GERD-time to change the definition or abandon the term?
    Aliment Pharmacol Ther. 2021;54:493-494.
    >> Share

    July 2021
  33. KIM YD, Wang J, Shibli F, Poels KE, et al
    No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
    Aliment Pharmacol Ther. 2021 Jul 12. doi: 10.1111/apt.16464.
    >> Share

  34. ROGERS BD, Gyawali CP
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers?
    Aliment Pharmacol Ther. 2021;54:188-189.
    >> Share

  35. FRAZZONI M, Frazzoni L, de Bortoli N, Savarino E, et al
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:190-191.
    >> Share

  36. OUDE NIJHUIS RAB, Sweis R, Abdul-Razakq H, Schuitenmaker JM, et al
    Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring.
    Aliment Pharmacol Ther. 2021;54:144-152.
    >> Share

    June 2021
  37. RIBOLSI M, Frazzoni M, Marabotto E, De Carlo G, et al
    Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.
    Aliment Pharmacol Ther. 2021 Jun 28. doi: 10.1111/apt.16481.
    >> Share

  38. SALVO EM, Ferko NC, Cash SB, Gonzalez A, et al
    Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16407.
    >> Share

  39. YADAV Y, Talley NJ
    Editorial: microscopic colitis linked to NSAIDs but not proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;53:1324-1325.
    >> Share

    April 2021
  40. FRAZZONI M, Frazzoni L, De Bortoli N, Russo S, et al
    Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.
    Aliment Pharmacol Ther. 2021 Apr 15. doi: 10.1111/apt.16371.
    >> Share

    March 2021
  41. EUSEBI LH, Telese A, Cirota GG, Haidry R, et al
    Systmatic review with meta-analysis: Risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2021 Mar 11. doi: 10.1111/apt.16321.
    >> Share

  42. HUSSAIN N, Shung DL
    Editorial: vitamin K antagonists versus direct oral anticoagulants in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2021;53:751-752.
    >> Share

  43. LABENZ C, Schattenberg JM
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:673.
    >> Share

  44. SUGIYAMA T
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view.
    Aliment Pharmacol Ther. 2021;53:671-672.
    >> Share

  45. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:665-666.
    >> Share

  46. CELSA C, Camma C
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle.
    Aliment Pharmacol Ther. 2021;53:663-664.
    >> Share

    February 2021
  47. ABDEL-AZIZ Y, Metz DC, Howden CW
    Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
    Aliment Pharmacol Ther. 2021 Feb 16. doi: 10.1111/apt.16295.
    >> Share

    January 2021
  48. LEUNG WK, Cheung KS, Li B, Law SYK, et al
    Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2021 Jan 24. doi: 10.1111/apt.16272.
    >> Share

  49. GOURIOU C, Bouguen G, Lahmek P, Pelaquier A, et al
    Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists.
    Aliment Pharmacol Ther. 2021 Jan 5. doi: 10.1111/apt.16236.
    >> Share

    December 2020
  50. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Impact of proton pump inhibitors on cytochrome P450 activity assessed by (13) C-aminopyrine breath test in patients with cirrhosis.
    Aliment Pharmacol Ther. 2020 Dec 28. doi: 10.1111/apt.16239.
    >> Share

    November 2020
  51. CHAUDHARY S, Mackay D, Pell JP, Morris J, et al
    Upper gastrointestinal bleeding in Scotland 2000-2015: trends in demographics, aetiology and outcomes.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16170.
    >> Share

    September 2020
  52. VERMORKEN AJM, Zhu J, Cui Y
    Letter: does Helicobacter pylori infection limit the health effects of the Mediterranean diet?
    Aliment Pharmacol Ther. 2020;52:935-936.
    >> Share

  53. LEE PL, Suk FM, Kang YN
    Letter: does tranexamic acid reduce the need for surgery in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;52:1088-1089.
    >> Share

  54. MARCUS EA, Pisegna JR
    Editorial: tegoprazan-the newest advance in the management of acid-related diseases.
    Aliment Pharmacol Ther. 2020;52:1074-1075.
    >> Share

    August 2020
  55. MEI LI C, Brusselaers N
    Letter: safety of proton pump inhibitors during pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:740-741.
    >> Share

  56. ACAR S, Keskin-Arslan E, Uysal N, Karadas B, et al
    Letter: safety of proton pump inhibitors during pregnancy.
    Aliment Pharmacol Ther. 2020;52:739.
    >> Share

    July 2020
  57. LABENZ C, Worns MA, Adarkwah CC, Galle PR, et al
    Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study.
    Aliment Pharmacol Ther. 2020 Jul 30. doi: 10.1111/apt.16008.
    >> Share

  58. CHO YK, Choi MG, Choi SC, Lee KM, et al
    Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
    Aliment Pharmacol Ther. 2020 Jul 23. doi: 10.1111/apt.15865.
    >> Share

  59. LASERNA-MENDIETA EJ, Casabona S, Guagnozzi D, Savarino E, et al
    Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.
    Aliment Pharmacol Ther. 2020 Jul 17. doi: 10.1111/apt.15957.
    >> Share

  60. SCHNOLL-SUSSMAN F, Katz PO
    Letter: bone fracture risk among older long-term users of proton pump inhibitors. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:408.
    >> Share

  61. SUGIYAMA T
    Letter: bone fracture risk among older long-term users of proton pump inhibitors.
    Aliment Pharmacol Ther. 2020;52:407-408.
    >> Share

  62. MA ZF, Deraman MA, Coyle C, Lee YY, et al
    Editorial: simultaneous, prolonged monitoring of the acid pocket and oesophageal reflux. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:398-399.
    >> Share

  63. KATZ PO, Castell DO
    Editorial: simultaneous prolonged monitoring of the acid pocket and oesophageal reflux.
    Aliment Pharmacol Ther. 2020;52:397-398.
    >> Share

    June 2020
  64. YUAN J, Zhang C, Sparks JA, Malspeis S, et al
    Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Jun 29. doi: 10.1111/apt.15834.
    >> Share

  65. PAPAEFTHYMIOU A, Doulberis M, Polyzos SA, Katsinelos P, et al
    Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma.
    Aliment Pharmacol Ther. 2020;51:1215-1216.
    >> Share

  66. GANTUYA B, El-Serag HB, Yamaoka Y
    Letter: are microbes other than Helicobacter pylori associated with gastric cancer? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1447-1449.
    >> Share

  67. HE C, Peng C, Xia Z, Lu N, et al
    Letter: are microbes other than Helicobacter pylori associated with gastric cancer?
    Aliment Pharmacol Ther. 2020;51:1446-1447.
    >> Share

  68. SUN Y
    Letter: Helicobacter pylori eradication treatment and the risk of oesophageal adenocarcinoma.
    Aliment Pharmacol Ther. 2020;51:1452-1453.
    >> Share

    May 2020
  69. TWUM-BARIMAH E, Abdelgadir I, Gordon M, Akobeng AK, et al
    Systematic review with meta-analysis: the efficacy of tranexamic acid in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2020 May 3. doi: 10.1111/apt.15761.
    >> Share

  70. ZHANG C, Li N, An Y
    Letter: the relationship between Helicobacter pylori and coronary heart disease.
    Aliment Pharmacol Ther. 2020;51:999.
    >> Share

    March 2020
  71. KUMAR S, Metz DC, Ginsberg GG, Kaplan DE, et al
    Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2020 Mar 4. doi: 10.1111/apt.15677.
    >> Share

    January 2020
  72. MACKE L, Schulz C, Koletzko L, Malfertheiner P, et al
    Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.
    Aliment Pharmacol Ther. 2020 Jan 28. doi: 10.1111/apt.15604.
    >> Share

  73. LI CM, Zhernakova A, Engstrand L, Wijmenga C, et al
    Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy.
    Aliment Pharmacol Ther. 2020 Jan 7. doi: 10.1111/apt.15610.
    >> Share

  74. MCPHERSON SJ, Hammond CJ
    Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2020;51:311-312.
    >> Share

  75. BARDOU M, Barkun AN
    Editorial: how can we best promote the routine use of scores that are accurate at predicting outcomes in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;51:305-306.
    >> Share

  76. PAPAEFTHYMIOU A, Doulberis M, Polyzos SA, Katsinelos P, et al
    Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease.
    Aliment Pharmacol Ther. 2020;51:313-314.
    >> Share

  77. STANLEY A
    Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding. Author's reply.
    Aliment Pharmacol Ther. 2020;51:312-313.
    >> Share

  78. KURLANDER JE, Rubenstein JH
    Editorial: moving towards the appropriate use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2020;51:175-176.
    >> Share

  79. SCHNOLL-SUSSMAN F, Katz PO
    Editorial: moving towards appropriate use of proton pump inhibitors. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:177.
    >> Share

  80. SCHEIMAN JM
    Commentary: cardioprotective aspirin and gastroduodenal ulcers.
    Aliment Pharmacol Ther. 2020;51:203.
    >> Share

    October 2019
  81. GHOSH G, Schnoll-Sussman F, Mathews S, Katz PO, et al
    Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns?
    Aliment Pharmacol Ther. 2019 Oct 30. doi: 10.1111/apt.15522.
    >> Share

  82. SAFFOURI E, Blackwell C, Laursen SB, Laine L, et al
    The Shock Index is not accurate at predicting outcomes in patients with upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2019 Oct 23. doi: 10.1111/apt.15541.
    >> Share

  83. GUO CG, Cheung KS, Zhang F, Chan EW, et al
    Risks of hospitalization for upper gastrointestinal bleeding in selective serotonin reuptake inhibitors users after Helicobacter pylori eradication therapy: a propensity score matching analysis.
    Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15507.
    >> Share

    April 2019
  84. WONG GL, Ma AJ, Deng H, Ching JY, et al
    Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding.
    Aliment Pharmacol Ther. 2019;49:912-918.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016